NCT06042764RecruitingPhase 2
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of Novel Coronavirus Broad-spectrum Neutralizing Antibody SA55 Injection in the Treatment of Mild/Moderate COVID-19 Patients
Sinovac Life Sciences Co., Ltd.1 site in 1 country150 target enrollmentStarted: August 31, 2023Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients
Study Overview
Brief Summary
Evaluating the efficacy and safety of SA55 injection in light/medium COVID-19 patients
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female aged ≥ 18 years on the day of enrollment;
- •On the day of enrollment, novel coronavirus nucleic acid test was positive and/or novel coronavirus antigen test was positive;
- •On the day of enrollment, it meets the criteria for mild or medium COVID-19 cases, and the time from the first COVID-19 infection related symptoms is within 72 hours;
- •Within 24 hours before enrollment, one or more of the following symptoms or signs must be present: a. fever, b. cough, c. sore throat, d. nasal congestion/runny nose, e. headache, f. muscle pain, g. shortness of breath/difficulty breathing, h. nausea, i. fatigue, j. vomiting, k. diarrhea;
- •Subjects (male and female of childbearing age) and their sexual partners voluntarily take effective contraceptive measures within 6 months after signing the informed consent form and administering the experimental drug, and do not have plans to donate sperm or eggs;
- •At rest, when inhaling air, the oxygen saturation is greater than 93%;
- •Subjects voluntarily participate in the experiment and sign an informed consent form before the start of the study.
Exclusion Criteria
- •Individuals who are known to be allergic to the investigational drug, any component in the preparation, or other similar drugs;
- •Individuals weighing less than 40 kg;
- •There are comorbidities that require surgery within one month, or comorbidities that are considered life-threatening within one month;
- •Before screening, he has received neutralizing antibody drugs from COVID-19, or received human immunoglobulin or convalescent plasma treatment from convalescent patients within 3 months, or received small molecule drugs from COVID-19 within 7 days;
- •Suspected or confirmed to have combined serious and active bacterial, fungal, viral or other infections (except for COVID-19 infection), such as acute systemic infection, the researcher believes that intervention measures may pose a risk;
- •Individuals who tested positive for influenza A/B virus antigens during screening;
- •Plan to become pregnant within 6 months, already pregnant, or breastfeeding;
- •Participated in clinical trials of other drugs or medical devices within 3 months prior to screening;
- •Having/having suffered from severe neurological disorders (epilepsy, convulsions, or seizures) or mental illness, or having a family history of mental illness;
- •Suffering from/having previously suffered from severe neurological diseases or other serious illnesses that the researcher has determined to be unsuitable for participation in the study (including but not limited to current systemic infections, uncontrolled autoimmune diseases, uncontrolled immunodeficiency diseases, history of myocardial infarction or heart disease, etc.);
- •Unable to cooperate with the follow-up of the study, or unable to guarantee the non use of concomitant drugs/vaccines/treatments prohibited by this protocol during the study period (see section 6.4.2);
- •The researcher believes that due to other reasons, it is not suitable to participate in this study.
Arms & Interventions
SA55 Injection
Experimental
Group 1: 300 mg Group 2: 600 mg
Intervention: SA55 Injection (Drug)
Placebo
Placebo Comparator
Group 1: 0 mg Group 2: 0 mg
Intervention: SA55 Injection (Drug)
Outcomes
Primary Outcomes
Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients
Time Frame: from baseline to D3, D5, D7
Changes of novel coronavirus (SARS-CoV-2) load from baseline to D3, D5, D7
Secondary Outcomes
- Evaluate the safety of SA55 injection in mild or moderate COVID-19 patients(an average of 1 year)
- Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients (impact on virological indicators)((1) D9, D11, D15 (2) After administration (3) D3, D5, D7, D9, D11, D15)
- Evaluation of the efficacy of SA55 injection in mild or moderate COVID-19 patients (impact on clinical indicators)(an average of 1 year)
- Evaluating the immunogenicity of SA55 injection(an average of 1 year)
- Evaluate the pharmacokinetic characteristics of SA55 injection in mild or moderate COVID-19 patients(an average of 1 year)
- Evaluation of serum COVID-19 neutralizing activity at different time points(an average of 1 year)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Effect of Daily Oral Administration of Food Supplement NLC-V in Patients Diagnosed With COVID-19COVID-19NCT05226767Todos Medical, Ltd.31
Completed
Phase 3
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)SARS-CoV-2 Infection (COVID-19)NCT04657497Ono Pharmaceutical Co. Ltd155
Completed
Phase 2
Annexin A5 in Patients With Severe COVID-19 DiseaseSepsisCoronavirus InfectionNCT04748757Lawson Health Research Institute18
Completed
Phase 1
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumoniaCOVID19ARDSNCT04468971Cellenkos, Inc.45
Completed
Phase 1
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19Severe Acute Respiratory SyndromeCoronavirusSARS-CoV-2COVID-19NCT04449276CureVac280